Payment overview · 2025
General Payments
$2,474.50
119 reported records · 30 companies
Healthcare provider profile · identity verified
Gregory Lee Copeland, DO
Allopathic & Osteopathic Physicians|Family Medicine · CLOVIS, CA · NPI 1154528123
Verified facts
What the public records show
CMS Open Payments records show Gregory Lee Copeland, DO received $2,474.50 in general payments during 2025 across 119 reported records.
ABBVIE INC. accounted for 21.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Paxlovid, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $537.29 | 21.7% | 27 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $266.18 | 10.8% | 14 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $188.73 | 7.6% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $172.60 | 7.0% | 12 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $162.08 | 6.5% | 7 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $155.96 | 6.3% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $141.55 | 5.7% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $74.30 | 3.0% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $72.42 | 2.9% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $69.13 | 2.8% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $64.46 | 2.6% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $62.68 | 2.5% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $60.16 | 2.4% | 3 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $54.76 | 2.2% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $53.96 | 2.2% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $41.64 | 1.7% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.19 | 1.5% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $33.04 | 1.3% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $29.60 | 1.2% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.91 | 1.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $23.85 | 1.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.01 | 0.8% | 1 | 2025 |
| Becton, Dickinson and Company | Unresolved — no canonical attribution shown | $18.03 | 0.7% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.88 | 0.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.95 | 0.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.92 | 0.6% | 1 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.70 | 0.6% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $15.68 | 0.6% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $15.58 | 0.6% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $15.26 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,474.50 | 119 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $366.03 | 16 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $175.83 | 10 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $141.55 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $135.26 | 9 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $133.91 | 9 | 2025 |
Source payment records
|
|||||
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $125.44 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $117.81 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $103.55 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $100.11 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $90.33 | 5 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $86.96 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $79.17 | 4 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $75.12 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $70.92 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $69.13 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $64.46 | 4 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $57.69 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $53.96 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $44.56 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $44.31 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $38.69 | 3 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $36.00 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $33.04 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $32.75 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.93 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $29.60 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $24.91 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $23.85 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.89 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $20.89 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $19.90 | 1 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Becton, Dickinson and Company | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $15.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 43 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 16 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 49 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
49 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
43 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
99 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 304 | 106 |
| Levothyroxine Sodium | Levothyroxine Sodium | 222 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 193 | 66 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 192 | 48 |
| Gabapentin | Gabapentin | 168 | 59 |
| Lisinopril | Lisinopril | 152 | 52 |
| Losartan Potassium | Losartan Potassium | 151 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 129 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 127 | 41 |
| Tramadol Hcl | Tramadol Hcl | 126 | 38 |
| Omeprazole | Omeprazole | 122 | 39 |
| Metformin Hcl | Metformin Hcl | 118 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 106 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 105 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 101 | 36 |
| Furosemide | Furosemide | 100 | 42 |
| Eliquis | Apixaban | 99 | 25 |
| Simvastatin | Simvastatin | 98 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 88 | 29 |
| Azithromycin | Azithromycin | 80 | 65 |
| Trazodone Hcl | Trazodone Hcl | 76 | 30 |
| Alprazolam | Alprazolam | 69 | 20 |
| Clonazepam | Clonazepam | 65 | 17 |
| Carvedilol | Carvedilol | 62 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 19 |
| Montelukast Sodium | Montelukast Sodium | 55 | 16 |
| Potassium Chloride | Potassium Chloride | 52 | 13 |
| Fenofibrate | Fenofibrate | 51 | 13 |
| Famotidine | Famotidine | 50 | 18 |
| Ezetimibe | Ezetimibe | 49 | 20 |
| Synthroid | Levothyroxine Sodium | 49 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | 18 |
| Prednisone | Prednisone | 46 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 15 |
| Ozempic | Semaglutide | 43 | 11 |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Allopurinol | Allopurinol | 39 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 39 | 15 |
| Pregabalin | Pregabalin | 39 | 11 |
| Valsartan | Valsartan | 39 | suppressed |
| Lorazepam | Lorazepam | 38 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | 13 |
| Sertraline Hcl | Sertraline Hcl | 37 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 36 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 36 | 19 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 35 | suppressed |
| Diazepam | Diazepam | 33 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 32 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Temazepam | Temazepam | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | 13 |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Meloxicam | Meloxicam | 28 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 11 |
| Jardiance | Empagliflozin | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 26 | 12 |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 17 |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Methadone Hcl | Methadone Hcl | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 17 |
| Testosterone | Testosterone | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 11 |
| Finasteride | Finasteride | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 14 |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | 11 |
| Asa-Butalb-Caffeine-Codeine | Codeine/Butalbital/Asa/Caffein | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 13 |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | 11 |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,474.50 · 119 records | ABBVIE INC. | APRETUDE, Auvelity, BREZTRI, CAPVAXIVE, DOVATO, Dexcom G6 Transmitter, EVENITY, FANAPT, FREESTYLE LIBRE 3, GARDASIL 9, GEMTESA, GVOKE HYPOPEN, General - Therapies, JARDIANCE, Kerendia, Korlym, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PROLIA, QULIPTA, RECORLEV, REPATHA, REXULTI, RotarexS 6 F x 135 cm, Rybelsus, SHINGRIX, SYNTHROID, Symbravo, TRELEGY ELLIPTA, TZIELD, Tlando, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, YUPELRI, Yeztugo, ZAVZPRET, ZENPEP | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error